Similar Items: Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer
- Real‐World Survival Over 25 Years in Extensive‐Stage Small‐Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors
- Pooled survival and cost-effectiveness analysis of immune checkpoint inhibitors-based for metastatic non-small-cell lung cancer with PD-L1 lower than 1%
- Lactate‐Induced Liquid–Liquid Phase Separation of HIF‐1α Drives Myeloid Cell Polarization and Immune Evasion in Colorectal Cancer
- Prognostic and Predict Value of Peripheral Blood Circulating Tumor Cells Programmed Death‐Ligand 1 Expression and F‐18‐Fluorodeoxyglucose Metabolic Parameters in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer Cells
- Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer